We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Resistant Cancer Cells Flush Out Drugs

By Biotechdaily staff writers
Posted on 19 Dec 2005
Researchers have identified a mechanism that allows cancer cells to flush out chemotherapeutic drugs before they reach a concentration great enough to kill the cells.

Investigators at the Technion-Israel Institute of Technology (Haifa; Israel) were continuing studies on a mutated form of the ABCG2 transporter protein. More...
Previous work had shown that cells possessing this form of the protein were resistant to chemotherapy.

In the current study, published in the December 1, 2005, issue of Cancer Research, they used high-resolution electron microscopy to reveal that a line of MCF-7 breast cancer cells developed balloon-like extracellular vesicles that sequestered the anticancer drug mitoxantrone. The membrane of these extracellular vesicles contained microvilli-like invaginations protruding into the intravesicular lumen. The invaginations served to increase the surface area of the membrane and increase its efficiency in transporting the drug. After 12 hours of incubation with mitoxantrone, the estimated intravesicular drug concentration was nearly 1,000-fold higher than in the culture medium.

Senior author Dr. Yehuda Assaraf, professor of biology at the Technion, explained, "The mutated ABCG2 protein is found in large quantities in the extracellular membrane of these vesicles located among the neighboring cancer cells. It ‘cleans' the cancer cells of chemotherapy drugs such as mitoxantrone and collects them in these vesicles, which enlarge and inflate until the drug concentration is a thousand times greater than in the surrounding cell culture. This is a completely new resistance mechanism practiced by breast cancer cells to fight the lethal activities of anticancer drugs.”







Related Links:
Technion-Israel Institute of Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.